Elagolix: a promising oral GnRH antagonist for endometriosis-associated pain
Open accessThe claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
An oral GnRH antagonist (elagolix) was reported to be effective for reducing endometriosis-related symptoms.
“Recently, an oral GnRH antagonist (elagolix) was reported to be effective for reducing endometriosis‐related symptoms.”
From Extra-pelvic endometriosis: a review. (2020) · cites this paper as [98]
Unlike GnRH agonists, GnRH antagonists induce rapid and reversible suppression of ovarian hormone levels without the initial 1- to 2-week flare-up reaction.
“Unlike GnRH agonists, GnRH antagonists induce rapid and reversible suppression of ovarian hormone levels without the initial 1‐ to 2‐week flare‐up reaction,”
From Extra-pelvic endometriosis: a review. (2020) · cites this paper as [98]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Giudice, L. C. (2010) · New England Journal of Medicine · doi:10.1056/nejmcp1000274 · Cited by 1,924 · see citing works
Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist
Taylor, H. S., Giudice, L. C., Lessey, B. A., Abrao, M. S., Kotarski, J., Archer, D. F., Diamond, M. P., Surrey, E., Johnson, N. P., Watts, N. B., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1700089 · Cited by 511 · see citing works
Self-citationStruthers, R. S., Nicholls, A. J., Grundy, J. S., Chen, T., Jimenez, R., Yen, S. S. C., & Bozigian, H. P. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1695 · Cited by 127 · see citing works
Diamond, M. P., Carr, B. R., Dmowski, W. P., Koltun, W. D., O'Brien, C. F., Jiang, P. X., Burke, J., Jimenez, R., Garner, E. I. O., & Chwalisż, K. (2013) · Reproductive Sciences · doi:10.1177/1933719113497292 · Cited by 121 · see citing works
Chen, C., Wu, D., Guo, Z., Xie, Q., Reinhart, G. J., Madan, A., Wen, J., Chen, T., Huang, C. Q., Mi, C., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm8006454 · Cited by 120 · see citing works
Carr, B., Dmowski, W. P., O’Brien, C., Jiang, P., Burke, J., Jimenez, R., Garner, E., & Chwalisz, K. (2014) · Reproductive Sciences · doi:10.1177/1933719114549848 · Cited by 114 · see citing works
Ng, J., Chwalisz, K., Carter, D. C., & Klein, C. E. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-3845 · Cited by 110 · see citing works
Elagolix, an Oral GnRH Antagonist for Endometriosis-Associated Pain: A Randomized Controlled Study
Carr, B. R., Giudice, L. C., Dmowski, W. P., O’Brien, C., Jiang, P. X., Burke, J., Jimenez, R., Hass, S., Fuldeore, M. J., & Chwalisż, K. (2013) · Journal of Endometriosis and Pelvic Pain Disorders · doi:10.5301/je.5000157 · Cited by 64 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Extra-pelvic endometriosis: a review.
Hirata, T., Koga, K., & Osuga, Y. (2020) · Reproductive Medicine and Biology · doi:10.1002/rmb2.12340 · Cited by 107 · see citing works
Shebley, M., Polepally, A. R., Nader, A., Ng, J. W., Winzenborg, I., Klein, C. E., Noertersheuser, P., Gibbs, M. A., & Mostafa, N. M. (2020) · Clinical Pharmacokinetics · doi:10.1007/s40262-019-00840-7 · Cited by 68 · see citing works
- Authors
- Dun, E. C., & Taylor, H. S.
- Affiliations
- Yale University (US)
- Corresponding author
- Taylor, Hugh S.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2017-11-11
- Volume
- 8
- Issue
- 59
- Pages
- 99219-99220
- ISSN
- 1949-2553 (ISSN-L)
- PMC
- PMC5725085
- OpenAlex
- W2767323643
- Cited by
- 10
- References
- 8
- Citations by year
- 2026: 1 · 2024: 1 · 2021: 2 · 2020: 2 · 2019: 2 · 2018: 2
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- cc-by
- Locations
- Oncotarget (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (UL1TR001863)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
- Health Sciences › Medicine › Obstetrics and Gynecology › Endometrial and Cervical Cancer Treatments
- Keywords
- elagolix, GnRH antagonist, endometriosis, endometriosis-associated pain, oral drug delivery, chronic pelvic pain
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
